OTHER RELEVANT INFORMATION

October 21, 2022
Grifols' statement on articles published in certain Spanish media

October 3, 2022
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

September 26, 2022
Board of Directors communication in the context of considerable geopolitical uncertainty and market volatility

September 7, 2022
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

July 28, 2022
Grifols sold MedKeeper to affiliates of the US company Becton Dickinson for US$ 93 million

June 10, 2022
Information on the resolutions approved at the General Meeting of Shareholders on June 10, 2022

May 6, 2022
Call notice of the General Shareholders' Meeting of Grifols, S.A. 2022

April 28, 2022
Grifols restates the consolidated annual accounts of the fiscal year 2021

April 25, 2022
Grifols completes the acquisition of Biotest

April 12, 2022
Grifols obtains all regulatory approvals to close the Biotest acquisition

February 28, 2022
Audit Committee and Sustainability Committee reorganization, as well as the appointment of the new Lead Independent Director of Board of Directors

November 17, 2021
Grifols and GIC obtain authorization for their strategic agreement for USD 1 billion

October 5, 2021
Grifols closes its EUR 2 billion bond issuance to finance its investment in Biotest

September 27, 2021
Grifols initiate the launch of a €2bn equivalent senior unsecured notes

August 16, 2021
Consent solicitation results on the lenders under Credit Agreement and the European Investment Bank to amend certain provisions of the senior debt

August 6, 2021
Consent solicitation results on Secured and Unsecured Notes to amend certain provisions of the senior debt

July 30, 2021
Commencing a consent solicitation to amend certain provisions of the senior debt

July 30, 2021
Grifols signs an agreement with ImmunoTek to open 21 plasma centers and further advances on its expansion plan

June 30, 2021
Grifols announces a strategic investment from GIC of USD 1 billion

June 14, 2021
Termination of the buyback programme

June 11, 2021
Recurring information under the buy-back programme of shares

May 31, 2021
Recurring information under the buy-back programme of shares

May 31, 2021
Information on the specific dividend payment conditions

May 25, 2021
Recurring information under the buy-back programme of shares

May 21, 2021
Information on the resolutions approved at the General Meeting of Shareholders on May 21, 2021

May 17, 2021
Recurring information under the buy-back programme of shares

May 10, 2021
Recurring information under the buy-back programme of shares

May 3, 2021
Recurring information under the buy-back programme of shares

April 26, 2021
Recurring information under the buy-back programme of shares

April 19, 2021
Recurring information under the buy-back programme of shares

April 16, 2021
Notice of Annual General Shareholders' Meeting 2021

April 12, 2021
Recurring information under the buy-back programme of shares

April 7, 2021
Grifols advances in the execution of its expansion plan with the acquisition of 7 plasma centers in the U.S.

April 6, 2021
Recurring information under the buy-back programme of shares

March 29, 2021
Recurring information under the buy-back programme of shares

March 22, 2021
Recurring information under the buy-back programme of shares

March 12, 2021
Buy-back plan of shares

March 9, 2021
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen

March 1, 2021
Grifols acquires 25 U.S.-based plasma centers from BPL ensuring one million additional liters for fractionation

February 22, 2021
The Regulations of the Sustainability Committee

January 19, 2021
Grifols begins a new COVID-19 trial containing anti-SARS-CoV-2 polyclonal antibodies